Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

BTLA Antibodies and Uses Thereof

a technology of antibodies and antibodies, applied in the field of btla antibodies, can solve the problems of not being able to overcome the immunosuppressive mechanisms observed in cancer patients, and no satisfactory approach has been proven to induce potent immune responses against vaccines

Inactive Publication Date: 2012-03-15
INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention is about a new antibody called BTLA that blocks a protein called BTLA-HVEM, which is involved in the immune system. This antibody can be used to treat cancer or chronic infections in humans or animals. The invention also includes a vaccine and a kit for treating cancer or chronic infections that contains the BTLA antibody. The invention also includes a specific version of the BTLA antibody called BTLA8.2.

Problems solved by technology

To date, no satisfactory approach has been proven to induce potent immune responses against vaccines, especially in cancer patients.
Methods have yet to be devised to overcome the immunosuppressive mechanisms observed in cancer patients, and during chronic infections.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • BTLA Antibodies and Uses Thereof
  • BTLA Antibodies and Uses Thereof
  • BTLA Antibodies and Uses Thereof

Examples

Experimental program
Comparison scheme
Effect test

example

Abstract

[0148]PD-1 and BTLA are receptors that negatively regulate T-cell activation. We have investigated their respective expression on human T cell subsets and their regulation following activation and finally compared their role in the regulation of T cell functions since there is no side by side comparison of their respective distribution and function. BTLA is expressed on naive CD4 and CD8 T cells and its expression was down-regulated on Effector-type and Memory type CD8+ T cells. In contrast, PD-1 was preferentially expressed by Effector and Memory type CD4+ and CD8+ T cells rather than Naive T cells. Engagement of PD-1 and / or BTLA by agonistic specific monoclonal antibodies blocked by the same strength CD3 / CD28-mediated T cell proliferation and Th1 and Th2 cytokine secretion. However, blockade of PD-1 and / or BTLA engagement following allogenic stimulation of T cells by DCs, revealed a robust inhibitory effect of PD-1 as compared to BTLA and no additive effect was detected be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diametersaaaaaaaaaa
domain structureaaaaaaaaaa
binding affinityaaaaaaaaaa
Login to View More

Abstract

The invention relates to BTLA antibodies that block BTLA-HVEM interaction and uses thereof.

Description

FIELD OF THE INVENTION[0001]The invention relates to BTLA antibodies that blocks BTLA-HVEM interaction and uses thereof.BACKGROUND OF THE INVENTION[0002]Co-receptor signalling is an important mechanism for coordinating and tightly regulating immune responses. The usual scheme of activation of αβ T cells relies on positive signals given by peptide antigens presented by HLA class I or II. Co-receptor signals will either increase or prevent this activation.Among the negative signalling molecules, those belonging to CD28 / B7 families are by far the most studied. Three members of this family have been described: CTL-associated antigen-4 (CTLA-4), programmed death-1 (PD-1) and B and T lymphocyte attenuator (BTLA). They all play a role in the control of tolerance. They provide negative signals that limit, terminate and / or attenuate immune responses.[0003]BTLA (CD272) is the most recently described member of the CD28 family, it was first identified as a transcript highly specific to T helper...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61P37/04A61P35/00A61P31/00C12N5/16C07K16/28
CPCA61K2039/505C07K16/2818C07K2317/73C07K16/2878C07K2316/96C07K16/2827C07K2317/74A61P31/00A61P35/00A61P37/04Y02A50/30A61K39/3955C07K2317/54C07K2317/55C07K2317/565
Inventor OLIVE
Owner INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com